Scarica l'app Stockscreener
380.86
0.47%
-1.78
Dopo l'orario di chiusura:
380.86
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SYK Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$382.64
Aprire:
$379.56
Volume 24 ore:
852.66K
Relative Volume:
0.54
Capitalizzazione di mercato:
$145.55B
Reddito:
$23.22B
Utile/perdita netta:
$2.86B
Rapporto P/E:
51.47
EPS:
7.4
Flusso di cassa netto:
$3.58B
1 W Prestazione:
+1.13%
1M Prestazione:
+0.70%
6M Prestazione:
-2.25%
1 anno Prestazione:
+11.66%
Intervallo 1D:
$375.55
$381.07
Intervallo di 1 settimana:
$375.55
$385.40
Portata 52W:
$314.93
$406.19
Stryker Corp Stock (SYK) Company Profile
Nome
Stryker Corp
Settore
Industria
Telefono
(269) 385-2600
Indirizzo
1941 STRYKER WAY, PORTAGE, MI
Confronta SYK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYK
Stryker Corp
|
380.86 | 146.67B | 23.22B | 2.86B | 3.58B | 7.40 |
|
ABT
Abbott Laboratories
|
133.57 | 231.29B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.17 | 157.07B | 17.55B | 2.03B | 2.72B | 1.37 |
|
MDT
Medtronic Plc
|
83.74 | 104.07B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.10 | 44.71B | 5.54B | 4.18B | 623.10M | 7.00 |
Stryker Corp Stock (SYK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-26 | Ripresa | Citigroup | Buy |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-10 | Iniziato | Wolfe Research | Outperform |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-22 | Aggiornamento | Needham | Hold → Buy |
| 2024-01-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-10-20 | Iniziato | ROTH MKM | Buy |
| 2023-09-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-25 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2023-01-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-11-01 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-28 | Aggiornamento | Edward Jones | Hold → Buy |
| 2022-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-07-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-04-13 | Iniziato | Truist | Hold |
| 2022-03-16 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-03-15 | Ripresa | Evercore ISI | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2021-12-07 | Iniziato | Loop Capital | Buy |
| 2021-09-14 | Ripresa | Raymond James | Mkt Perform |
| 2021-07-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-06-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-10-06 | Iniziato | Northland Capital | Market Perform |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-04-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2020-04-01 | Downgrade | Goldman | Buy → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-08 | Iniziato | SunTrust | Hold |
| 2020-01-07 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2020-01-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2019-12-30 | Reiterato | BTIG Research | Buy |
| 2019-11-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-10-30 | Reiterato | BofA/Merrill | Buy |
| 2019-07-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-01-30 | Reiterato | Canaccord Genuity | Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Buy |
| 2019-01-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-08-16 | Iniziato | BTIG Research | Buy |
| 2018-06-27 | Iniziato | Bernstein | Mkt Perform |
| 2018-04-27 | Reiterato | Stifel | Buy |
Mostra tutto
Stryker Corp Borsa (SYK) Ultime notizie
Pressure Relief Devises Industry Overview: Innovations & Key - openPR.com
Barclays maintains Stryker stock Overweight rating, $443 target By Investing.com - Investing.com South Africa
Barclays maintains Stryker stock Overweight rating, $443 target - Investing.com
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
Here's How Much $1000 Invested In Stryker 20 Years Ago Would Be Worth Today - Benzinga
Stryker tops list of West Michigan’s largest publicly traded companies - Crain's Grand Rapids Business
Stryker's Profits Outshine Forecasts Thanks To Device Demand - Finimize
Jim Cramer on Stryker Corporation (SYK): “I Don’t Like It Enough” - Insider Monkey
Jim Cramer Had These 21 Stocks on His Radar - Insider Monkey
Stryker’s SWOT analysis: stock poised for growth amid strategic moves - Investing.com
Stryker corp VP sells shares worth $211,369 - Investing.com Australia
Stryker corp’s chief accounting officer sells $211,369 in shares By Investing.com - Investing.com South Africa
Stryker corp VP sells shares worth $211,369 By Investing.com - Investing.com Nigeria
Stryker corp’s chief accounting officer sells $211,369 in shares - Investing.com Australia
Stryker Hits Treace With Patent Suit Over Surgical Foot-Implants - Bloomberg Law News
Stryker Corporation: Is Its Tuck-in Acquisition Strategy to Ensure Market Leadership In The Med-Tech Landscape? - Smartkarma
Citigroup Raises Price Target for Stryker (SYK) to $455 | SYK Stock News - GuruFocus
Stryker wins FDA clearance for minimally invasive back pain treatment - Yahoo Finance
Stryker (SYK) Price Target Raised by Citi to $455 | SYK Stock Ne - GuruFocus
Stryker (NYSE:SYK) Expands Pain Therapy With FDA Clearance For OptaBlate BVN System - Yahoo Finance
USITC to investigate Fiagon after Stryker medical device infringement claims - MLex
SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System - Yahoo Finance
Stryker Receives FDA Clearance For OptaBlate System Aimed At Low Back Pain Relief: Retail’s Yet To React - Investing.com India
Stryker (SYK) Gains FDA Clearance for OptaBlate System - GuruFocus
Stryker (SYK) Secures FDA Clearance for OptaBlate Nerve Ablation System | SYK Stock News - GuruFocus
Stryker’s new system aims at chronic back pain relief - Investing.com
Breakthrough: FDA Approves Stryker's Revolutionary Nerve Ablation System for Chronic Back Pain Relief - Stock Titan
Stryker Stock: Analyst Estimates & Ratings - Barchart.com
Stryker Inks Deal to Buy One of Its Suppliers Stryker Corp. will pay $150 million for Gaymar Indu - Medical Product Outsourcing
Boston Sci Closes Division Sale to Stryker Corp. On Jan. 3, Boston Scientific Corp. completed the - Medical Product Outsourcing
Stryker Moves to Settle DOJ Probe - Medical Product Outsourcing
Stryker’s Bone Growth Division Sold to Olympus Corp. Stryker Corp. has inked a deal to sell - Medical Product Outsourcing
Insulet Adds Stryker Executive to Board - Medical Product Outsourcing
Former Stryker CEO Receives Lifetime Achievement Award from AdvaMed - Medical Product Outsourcing
Stryker Settles for $80 Million in Unapproved Device Sales Case - Medical Product Outsourcing
Stryker Snaps Up Concentric for $135M - Medical Product Outsourcing
First-Quarter Sales Strong at Stryker Corp. - Medical Product Outsourcing
Stryker: We’re Not Buying Smith & Nephew … Yet, But We’re Interested - Medical Product Outsourcing
SYK Q1 Earnings Call: Stryker Delivers Revenue Beat, Cites International Growth and Tariff Headwinds - Yahoo Finance
Top Executive Sells Stryker Shares in Major Transaction - TipRanks
Stryker Corp Shareholders Approve Incentive Plans By Investing.com - Investing.com India
Stryker Corporation (SYK) Shareholders Approve Key Incentive Pla - GuruFocus
Stryker at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Stryker Corp Shareholders Approve Incentive Plans - Investing.com
There May Be Reason For Hope In Stryker's (NYSE:SYK) Disappointing Earnings - Yahoo Finance
Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold) (NYSE:SYK) - Seeking Alpha
Why Stryker Corporation (SYK) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Stryker Director Makes a Multi-Million Dollar Stock Move! - TipRanks
Stryker declares an $0.84 per share quarterly dividend - Ortho Spine News
Stryker (SYK) Announces Steady Dividend with Promising Growth Forecast - GuruFocus
Stryker raises dividend to $0.84 per share for Q2 - Investing.com
Stryker Corp Azioni (SYK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.04%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):